To date, the prognosis of NSCLC is mainly based on the tumor-node-metastasis (TNM) staging system (2), histology (2), and predictive biomarker analyses, such as epidermal growth factor (EGFR) mutation (3), anaplastic lymphoma kinase (ALK) translocations (4), c-ros oncogene 1 (ROS1) rearrangement (5), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation (6). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.